MNPR 101-DFO*-89Zr - Monopar Therapeutics
Alternative Names: MNPR-101-DFO*-89ZrLatest Information Update: 27 May 2024
At a glance
- Originator Monopar Therapeutics
- Class Antineoplastics; Imaging agents; Monoclonal antibodies; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 01 Apr 2024 Preclinical trials in Solid tumours in USA (Parenteral) prior to April 2024
- 01 Apr 2024 Monopar Therapeutics plans a phase I trial in Solid tumours in Australia (NCT06337084)